Antengene announces xpovio® regulatory approval in macau for the treatment of relapsed and/or refractory multiple myeloma

Xpovio® (selinexor) is the first and only exportin 1 (xpo1) inhibitor approved in macau.  xpovio® has received regulatory approvals in   42 countries and regions including mainland of china, taiwan china, hong kong china, macau china, south korea, singapore and australia.
KPTI Ratings Summary
KPTI Quant Ranking